Actinogen is a neurotherapeutics developer realizing a revolutionary therapy so neurology patients and their families can live their best lives
Latest Summary Corporate Presentation
View PresentationThe Actinogen phase 2b/3 Alzheimer’s disease trial is now recruiting
The Xanamem® Pipeline
Diseases to be studied
Phase 2 placebo-controlled trials
Outlook
Biomarker analysis in patients with mild AD
Cognitive benefit in patients with early stages of AD
Pivotal trials focused on cognitive enhancement
Diseases to be studied
Phase 2 placebo-controlled trials
Outlook
Depression and cognitive impairment
Pivotal trials assessing both depression and cognitive impairment
Diseases to be studied
Phase 2 placebo-controlled trials
Outlook
Proof of concept in adolescent and young adult males
Pending alternative funding e.g. partnerships or grants
The Actinogen phase 2b/3 Alzheimer’s disease trial is now recruiting
Latest News
View all news
Latest Summary Corporate Presentation
View Presentation01 Jul 2025 | Herald Sun | |
30 Jun 2025 | Nine News Melbourne | |
30 Jun 2025 | PR Newswire | |
04 Jun 2025 | Courier Mail | |
15 May 2025 | Webcast Video Recording |
Stay updated
If you would like to receive our latest news and updates, you can join our email distribution list. Simply register your details.
Investors View Investor Centre
ASX Announcements
View all ASX AnnouncementsAnalyst REPORTS
-
08 Jul 2025
Edison Investment Research update
Actinogen Medical – XanaMIA study enrols 100th patient -
06 Apr 2025
Bioshares Edition 972:
Actinogen Medical – Progressing its Phase IIb/III Alzheimer’s Study -
13 Feb 2025
Edison Investment Research update
Actinogen Medical – XanaMIA Phase IIb/III study marches on -
15 Oct 2024
Edison Investment Research update
Actinogen Medical – A$11.1m capital raise completed